Abstract: A compound selected from Formula (I) hereinbelow: or a pharmaceutically acceptable salt thereof, wherein m is an integer from 0 to 2; n is an integer from 1 to 3; X is selected from the group consisting of CN, NO2, Cl, F, and H; Y is selected from the group consisting of Cl, F, Br, I and H; and Q and Z are, independently, selected from the group consisting of H, R1, SO2R1′, R1C(O)OR1″, SO2NR1′R1″, C(O)NR1′R1″, NR1′SO2R″1, wherein R1, R1′ and R1″ are independently selected from the group consisting of hydrogen, C1-4 alkyl, C3-6 cycloalkyl, C2-5 alkenyl, C2-5 alkynyl, heterocycloalkyl, aryl and aryl C1-4 alkyl; or R1′ and R1″ together form a 3 to 7 membered optionally substituted heterocyclic ring; wherein any substituents are selected from the group consisting of CN, aryl, CO2R, CO2NHR, OH, OR, NH2, halo, CF3, OCF3 and NO2; wherein R represents H, C1-4 alkyl, and C3-6 cycloalkyl; and A is phenyl or naphthyl, unsubstit

Abstract: Novel isoquinoline derivatives and methods of using them to treat various neurological indications are disclosed.

Abstract: Novel IL-8 receptor antagonists and methods of using them are provided.

Abstract: Sulphonamide compounds according to formula (I) or pharmaceutically acceptable salts thereof: wherein: Ar is naphthyl, phenyl or thienyl optionally substituted by one or more substituents selected from the group consisting of C1-6 alkyl optionally substituted by NR7R8, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkylthio, cyano, nitro, halogen, CF3, C2F5, NR7R8, CONR7R8, NR7COR8, S(O)pNR7R8, CHO, OCF3, SCF3, COR9, CH2OR9, CO2R9 or OR9 where p is 1 or 2 and R7, R8 and R9 are independently hydrogen or C1-6 alkyl. R1 and R2 are independently hydrogen or C1-6alkyl or together with the nitrogen atom to which they are attached form a 5- to 7-membered heterocyclic ring optionally substituted by Cl-6alkyl and optionally containing a further heteroatom selected from nitrogen, sulphur or oxygen, the nitrogen atom being substituted by hydrogen, C1-6 alkyl or cycloC3-7alkyl; R3 is hydrogen or C1-6 alkyl; X is oxygen, sulphur or a bond; n is 2 or 3; and m is 1 or 2; are provided.

Abstract: The present invention relates to novel compounds and a novel use of phenyl ureas in the treatment of disease states mediated by the chemokine Interleukin-8 (IL-8).

Abstract: Salicylanilide derivatives which are macrophagescavenger receptor antagonists are provided. Methods of treating cardiovascular disease comprising administration of the present compounds are also provided. The present compounds inhibit lipid accumulation within macrophage-derived foam cells.

Abstract: Compounds of formula (I) wherein R is hydroxy, hydrogen, alkenyl, alkynyl or aryl, and R1 is aryl or heteroaryl, are useful in the treatment and prophylaxis of conditions mediated by CD23 or TNF.

Abstract: Inhibitors of the Production of s-CD23 and the secretion of TNF are provided.

Abstract: The present invention is to the discovery of a novel CD23 processing enzyme which is of importance in the human immune response and regulation of IgE production, and is a protein expressed on the surface of a variety of cells.

Abstract: This invention provides for a method of treating a chemokine mediated disease, wherein the chemokine is one which binds to an IL-8 &agr; or &bgr; receptor and which method comprises administering an effective amount of a compound of Formular (I) or a pharmaceuticlly acceptable salt thereof. In particular the chemokine is IL-8.

Abstract: The present invention relates to the use of phenyl ureas in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

Abstract: The present invention relates to the novel use of phenyl ureas in the treatment of disease states mediated by the chemokine, Interleukin-8 (I-8).

Abstract: This invention relates to novel compounds of Formula (I), and a novel use of these compounds in treating chemokine mediated diseases, wherein the chemokine binds to an IL-8 a or b receptor.

Abstract: This invention relates to novel compounds of Formula (1), pharmaceutical compositions and their use in the treatment of disease states mediated by the chemokine, Interleukins-8 (IL-8).

Abstract: This invention relates to the novel use of phenyl ureas in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

Abstract: The present invention relates to novel pyridine derivatives and compositions comprising them useful in the treatment of disease states mediated by the chemokine Interleukin-8.

Abstract: This invention relates to compounds of Formula (I), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

Abstract: Novel bicyclic aryl/bicyclic heterocyclic ring containing compounds having a combined 5HT.sub.1A, 5HT.sub.1B and 5HT.sub.1D receptor antagonistic activity are provided.

Abstract: This invention relates to the use of phenyl ureas of formulas (I) and (II) in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8). The variables of (I) and (II) are defined herein.

Abstract: Compounds of the general formula (I), and pharmaceutically acceptable salts thereof, ##STR1## in which X.sub.1 --(CH.sub.2).sub.x --X.sub.2 and the aromatic carbon atoms to which they are attached form a 5-7 membered ring,wherein:one of X.sub.1 and X.sub.2 is O, S or CH.sub.2 and the other is CH.sub.2 ;x is 1, 2 or 3;R.sub.1 is hydrogen, amino, halo, C.sub.1-6 alkyl, hydroxy or C.sub.1-6 alkoxy;R.sub.2 is hydrogen, halo, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, nitro, amino or C.sub.1-6 alkylthio;R.sub.3 is hydrogen, halo, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or amino;R.sub.4 and R.sub.5 are independently hydrogen or C.sub.1-6 alkyl;Y is O or NH;Z is of sub-formula (a), (b) or (c): ##STR2## wherein n.sup.1 is 1, 2, 3 or 4; n.sup.2 is 1 or 2; n.sup.3 is 2, 3, 4 or 5;q is 0, 1, 2 or 3; p is 0, 0 or 2; m is 0, 1 or 2;R.sub.a is hydrogen or a lipophilic group, such as C.sub.1-12 alkyl or aralkyl; orR.sub.a is (CH.sub.2).sub.r --R.sub.10 wherein r is 2 or 3 and R.sub.10 is selected from cyano, hydroxyl, C.sub.